PPARA and neoplasm: The activation of PPAR-α also improves anti-tumor immunity in PD-1 blockade cancer immunotherapy by reprogramming CD8+ T-cell metabolism from glycolysis to increased mitochondrial OXPHOS and FAO, supporting the extra energy demands of effector CTLs, thus lengthening the survival and potentiating activity (65, 66).